卵巢上皮-间质肿瘤中B7-H3、B7-H4的表达及临床病理意义

被引：2
|
作者：
廖林虹 [1 ]
于晓红 [2 ]
机构：
[1] 江西省赣州市妇幼保健院病理科
[2] 江西省妇幼保健院病理科
来源：
临床与实验病理学杂志 | 2012年 / 28卷 / 07期
关键词：
卵巢肿瘤; 上皮-间质; B7-H3; B7-H4; mRNA; 蛋白表达;
D O I：
10.13315/j.cnki.cjcep.2012.07.025
中图分类号：
R737.31 [卵巢肿瘤];
学科分类号：
摘要：
目的探讨B7-H3、B7-H4在卵巢上皮-间质肿瘤中的表达及其临床病理意义。方法用RT-PCR技术及免疫组化PV9000两步法研究86例卵巢恶性上皮-间质肿瘤(恶性组),40例卵巢交界性上皮-间质肿瘤(交界组)和40例卵巢良性上皮-间质肿瘤(良性组)B7-H3与B7-H4mRNA及蛋白表达情况,并结合临床病理参数进行分析。结果 B7-H3、B7-H4mRNA在3组卵巢肿瘤组织中均有表达,且各自的3组卵巢肿瘤组织的mRNA光密度值差异均有统计学意义(P<0.05);B7-H3与B7-H4蛋白在恶性组中均呈细胞质和(或)细胞膜表达,其中B7-H3阳性率为81.4%(70/86),明显高于交界组22.5%(9/40)和良性组5.0%(2/40)的表达,差异有统计学意义(P<0.05);B7-H4阳性率为77.9%(67/86),明显高于交界组35.0%(14/40)和良性组5.0%(2/40)的表达,差异有统计学意义(P<0.05)。恶性组的卵巢癌组织中B7-H3蛋白在非黏液性卵巢癌中较黏液性卵巢癌高表达,差异有显著性(P<0.01),与临床分期、病理分级、患者年龄、腹水细胞学和淋巴结转移差异均无统计学意义(P>0.05)。B7-H4蛋白表达与组织病理学类型、临床分期、病理分级、患者年龄、腹水细胞学和淋巴结转移差异均无统计学意义(P>0.05)。结论 B7-H3与B7-H4在卵巢恶性上皮-间质肿瘤表达提示其可能与肿瘤的发生、发展有关,可为卵巢恶性肿瘤的诊断及治疗提供新的依据。
引用
收藏
页码：775 / 779
页数：5
相关论文
共 15 条
  • [1] Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Zang X,Sullivan PS,Soslow RA,Waitz R,Reuter VE,Wilton A, et al. Modern Pathology . 2010
  • [2] MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3 : potential implications for immune based therapy of human solid tumors. Xu H,Cheung IY,Guo HF, et al. Cancer Research . 2009
  • [3] The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Chen YW,Tekle Cet al. Current Cancer Drug Targets . 2008
  • [4] Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Kryczek I,Wei S,Zhu G, et al. Cancer Research . 2007
  • [5] Systemic therapy for ovarian cancer:Current status and new treatments. Ozols RF. Seminars in Oncology . 2006
  • [6] Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. Choi IH,Zhu G,Sica GL,et al. The Journal of Immunology . 2003
  • [7] B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Chapoval AI,Ni J,Lau JS,et al. Nature Immunology . 2001
  • [8] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:a phase II trail of the Gynecologic Oncology Group. Bookman MA,Darcy KM,Clarke-Pearson D,et al. Journal of Clinical Oncology . 2003
  • [9] B7-H4在卵巢浆液性癌组织中的表达及其临床意义
    廖林虹
    于晓红
    [J]. 实用癌症杂志, 2010, 25 (05) : 473 - 475+482
  • [10] B7-H3的免疫调控及最新研究进展[J]. 廖林虹,于晓红.  细胞与分子免疫学杂志. 2009(11)
12